We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Precipio Inc | NASDAQ:PRPO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 5.7499 | 5.50 | 6.20 | 0 | 12:00:05 |
This marks the first substantial customer for one of Precipio’s technologies. A first order has been placed - and delivered.
Tennessee Oncology is one of the nation’s largest community-based cancer care specialists. With 90 physicians in 40 locations, Tennessee Oncology deploys a POL (Physician Office Laboratory) which services their physicians. The laboratory runs a full suite of diagnostic services; with the addition of HemeScreen, it is able to provide better turnaround time and a higher quality of service to its physicians.
Tennessee Oncology is part of OneOncology, a partnership of independent community oncology practices working together to deliver comprehensive cancer care that includes the West Cancer Center and New York Cancer and Blood Specialists. Combined, OneOncology has more than 200 oncology providers.
Based on current volume within Tennessee Oncology’s laboratory, and taking into consideration the affiliate practices within OneOncology, Precipio anticipates revenues of approximately $750,000 per year from this group alone, scaling up beginning in Q4-2019. Furthermore, we estimate that in the US there are likely over 50 similar-size potential customers such as Tennessee Oncology for Precipio’s HemeScreen assay.
HemeScreen clinical value
Under the published WHO guidelines, patients with Myeloproliferative Disorders (MPD) and Myelodysplastic syndrome (MDS) are required to be tested for the gene mutations included in the HemeScreen panel. These mutations include both therapeutic mutations which indicate the patient’s potential response to a targeted therapy; and also prognostic mutations, which indicate how aggressive the tumor may be.
These insights into the patient’s condition are critical to the immediate therapy decisions a physician must make, and therefore time is of the essence to receive those results. Many laboratories currently provide a turn-around-time (TAT) of 2-3 weeks for results on all 4 mutations; this can become a substantial waiting period for physicians and their patients awaiting this critical information to begin treatment.
Due to the efficiency of the technology utilized in HemeScreen, laboratories can achieve a rapid TAT of 1-2 days, significantly shortening the waiting time for these critical results for physicians and their patients.
“By offering an attractive solution for laboratories to generate revenue and profit, we add economic value as well as speed up clinical decision making for the physicians and patients”., said Stephen Miller, Precipio’s Chief Commercial Officer.
Two Hospital / Laboratory Implementation Models
Precipio has established two implementation models for HemeScreen to match the various size and capabilities of hospitals and laboratories within the market:
For more information on either of these models, please contact us at hs@precipiodx.com.
About Precipio
Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine and Harvard’s Dana-Farber Cancer Institute, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit www.precipiodx.com.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements,” within the meaning of federal securities laws, including statements related to ICP technology, including financial projections related thereto and potential market opportunity, plans and prospects and other statements containing the words “anticipate,” “intend,” “may,” “plan,” “predict,” “will,” “would,” “could,” “should,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the known risks, uncertainties and other factors described in the Company’s definitive proxy statement filed on April 19, 2019 , the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2019 and on the Annual Report on Form 10-K for the year ended December 31, 2018 as well as the Company’s prior filings and from time to time in the Company’s subsequent filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. All information in this press release is as of the date of the release and the Company does not undertake any duty to update this information, including any forward-looking statements, unless required by law.
Inquiries:
investors@precipiodx.com
+1-203-787-7888
1 Year Precipio Chart |
1 Month Precipio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions